Physician profile
Celina C Bernabe
NPI 1063518546
$94,710.85
in general payments reported to CMS, 2019-2025
41 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,249 · 2020: $13K · 2021: $7,852 · 2022: $20K · 2023: $15K · 2024: $13K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Food and Beverage: $13K · Travel and Lodging: $4,887 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,845 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,399.24 |
| Food and Beverage | $12,608.67 |
| Travel and Lodging | $4,887.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,845.00 |
| Education | $223.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $62,901.14 | 2019-2025 | Ruconest |
| Astrazeneca Pharmaceuticals Lp | $8,238.35 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $6,233.12 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Genzyme Corporation | $2,018.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,858.82 | 2020-2025 | Takhzyro, Hyqvia, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,400.04 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,359.89 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,349.44 | 2019-2024 | |
| Genentech USA, INC. | $1,186.15 | 2019-2025 | Xolair |
| Adma Biomanufacturing LLC | $1,065.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,059.98 | 2019-2025 | |
| Abbvie INC. | $713.95 | 2021-2024 | Rinvoq, Ubrelvy |
| Pfizer INC. | $653.01 | 2019-2025 | |
| Amgen INC. | $625.37 | 2021-2025 | Tezspire |
| Leo Pharma INC. | $482.24 | 2022-2025 | Adbry |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $463.64 | 2023-2025 | |
| Grifols USA, LLC | $393.42 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $379.49 | 2021-2024 | Orladeyo |
| Bio Products Laboratory USA, INC. | $331.01 | 2019-2023 | Coagadex, Gammaplex |
| Incyte Corporation | $327.13 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $180.19 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $179.09 | 2024-2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $176.26 | 2025 | Orladeyo |
| Blueprint Medicines Corporation | $175.80 | 2021-2024 | Ayvakit |
| Kaleo, INC. | $140.55 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $135.26 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.86 | 2019-2022 | |
| Octapharma USA, INC. | $84.14 | 2020-2024 | Octagam Immune Globulin (Human), Cutaquig |
| Hikma Pharmaceuticals USA | $73.62 | 2023-2025 | Ryaltris |
| Alk-Abello, INC | $72.44 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $62.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $61.12 | 2019-2021 | |
| Shire North American Group INC | $50.81 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $43.47 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $29.87 | 2022 | |
| Lilly USA, LLC | $29.29 | 2025 | Ebglyss |
| Allergan, INC. | $21.54 | 2019 | |
| Gc Biopharma USA, INC. | $15.96 | 2025 | Alyglo |
| Boston Scientific Corporation | $14.43 | 2020 | |
| Mylan Specialty L.P. | $13.30 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celina Bernabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.